| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $2,999,996 | 1 | 33 |
Sells | $10,477 | 2 | 67 |
| Manning Paul B | director | 1 | $3M | 0 | $0 | $3M |
| Nichols William Garrett | Chief Medical Officer | 0 | $0 | 2 | $10,477 | $-10,477 |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $3M and sold $10,477 worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $6.34M and sold $2.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $3M.
The last purchase of 550,458 shares for transaction amount of $3M was made by Manning Paul B (director) on 2026‑02‑23.
| 2026-02-23 | Manning Paul B | director | 550,458 1.0995% | $5.45 | $3M | +5.63% | ||
| 2025-07-28 | Sale | Nichols William Garrett | Chief Medical Officer | 937 0.0018% | $6.98 | $6,540 | -18.66% | |
| 2025-06-30 | Sale | Nichols William Garrett | Chief Medical Officer | 781 0.0015% | $5.04 | $3,936 | +11.26% | |
| 2025-03-19 | Sale | Tak Paul Peter | Chief Executive Officer | 400 0.0009% | $9.00 | $3,601 | -38.76% | |
| 2025-03-18 | Sale | Tak Paul Peter | Chief Executive Officer | 25,772 0.0576% | $8.77 | $226,023 | -38.21% | |
| 2025-03-18 | Sale | Barone Francesca | Chief Scientific Officer | 32,146 0.0718% | $8.76 | $281,673 | -38.21% | |
| 2025-03-18 | Sale | Nichols William Garrett | Chief Medical Officer | 45,316 0.1012% | $8.76 | $396,995 | -38.21% | |
| 2025-03-17 | Sale | Tyagarajan Seshu | Chief Technology Officer | 31,278 0.0703% | $8.82 | $275,947 | -38.17% | |
| 2025-03-17 | Sale | Schoch Charles | See Remarks | 5,000 0.0112% | $8.83 | $44,169 | -38.17% | |
| 2025-01-15 | Sale | Tak Paul Peter | Chief Executive Officer | 21,704 0.0476% | $7.22 | $156,811 | -30.13% | |
| 2025-01-15 | Sale | Barone Francesca | Chief Scientific Officer | 13,534 0.0297% | $7.22 | $97,783 | -30.13% | |
| 2025-01-15 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,322 0.0314% | $7.22 | $103,476 | -30.13% | |
| 2025-01-15 | Sale | Nichols William Garrett | Chief Medical Officer | 10,428 0.0229% | $7.22 | $75,342 | -30.13% | |
| 2025-01-15 | Sale | Schoch Charles | See Remarks | 9,511 0.0209% | $7.22 | $68,717 | -30.13% | |
| 2025-01-08 | Sale | Tak Paul Peter | Chief Executive Officer | 21,172 0.0454% | $8.22 | $173,996 | -36.03% | |
| 2025-01-08 | Sale | Barone Francesca | Chief Scientific Officer | 13,673 0.0293% | $8.22 | $112,367 | -36.03% | |
| 2025-01-08 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,545 0.0312% | $8.22 | $119,534 | -36.03% | |
| 2025-01-08 | Sale | Nichols William Garrett | Chief Medical Officer | 10,799 0.0231% | $8.22 | $88,749 | -36.03% | |
| 2025-01-08 | Sale | Schoch Charles | See Remarks | 9,971 0.0214% | $8.22 | $81,944 | -36.03% | |
| 2024-12-16 | Manning Paul B | director | 1.25M 3.786% | $6.00 | $7.5M | -7.79% |
| Manning Paul B | director | 2763527 5.0337% | $23.49M | 4 | 0 | <0.0001% |
| Nichols William Garrett | Chief Medical Officer | 52493 0.0956% | $446,190.50 | 0 | 8 | |
| Aguilar-Cordova Estuardo | 10 percent owner | 919461 1.6748% | $7.82M | 0 | 6 | |
| Tak Paul Peter | Chief Executive Officer | 225740 0.4112% | $1.92M | 3 | 7 | <0.0001% |
| Martell Christopher | director | 152000 0.2769% | $1.29M | 3 | 0 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 96527 0.1758% | $820,479.50 | 1 | 6 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 85512 0.1558% | $726,852.00 | 2 | 6 | <0.0001% |
| PAPA JOSEPH C | director | 38032 0.0693% | $323,272.00 | 2 | 0 | <0.0001% |
| Schoch Charles | See Remarks | 38038 0.0693% | $323,323.00 | 0 | 5 | |
| Canepa John J | Chief Financial Officer | 10125 0.0184% | $86,062.50 | 1 | 0 | <0.0001% |
| Nguyen Diem | director | 10000 0.0182% | $85,000.00 | 1 | 0 | <0.0001% |
| Caffo Nathan | Chief Business Officer | 6000 0.0109% | $51,000.00 | 1 | 0 | <0.0001% |
| Amello Jason | Chief Financial Officer | 5568 0.0101% | $47,328.00 | 2 | 0 | <0.0001% |
$70,111,730 | 78 | 26.02% | $525.72M | |
$16,169,789 | 40 | 7.44% | $476.44M | |
$1,323,997 | 34 | 0.21% | $428.22M | |
$2,303,314 | 30 | 166.84% | $419.47M | |
$112,238,340 | 19 | 39.16% | $448.14M | |
$2,516,932 | 19 | -15.78% | $426.54M | |
Candel Therapeutics, Inc. (CADL) | $22,365,077 | 19 | -27.47% | $466.66M |
$133,809,976 | 13 | 31.29% | $461.33M | |
$65,355,913 | 13 | -3.42% | $416.01M | |
$57,263,116 | 11 | -8.37% | $451.16M | |
$94,283,940 | 10 | 50.27% | $534.63M | |
$105,345,724 | 9 | -19.24% | $499.4M | |
$62,616,785 | 8 | -7.00% | $549.09M | |
$13,043,783 | 8 | 732.82% | $521.78M | |
$15,652,720 | 6 | -4.77% | $472.82M | |
$88,549,962 | 5 | -16.91% | $451.67M | |
$1,746,565 | 4 | -29.05% | $528.48M | |
$2,720,023 | 3 | -11.76% | $451.93M | |
$7,234,370 | 3 | -3.34% | $506.67M |
| Increased Positions | 45 | +54.88% | 2M | +8.01% |
| Decreased Positions | 31 | -37.8% | 896,644 | -3.95% |
| New Positions | 13 | New | 303,513 | New |
| Sold Out Positions | 13 | Sold Out | 584,269 | Sold Out |
| Total Postitions | 96 | +17.07% | 24M | +4.06% |
| Fmr Llc | $44,790.00 | 14.97% | 8.23M | -50 | <0.01% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $14,038.00 | 4.69% | 2.58M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $12,944.00 | 4.33% | 2.38M | +77,485 | +3.37% | 2025-09-30 |
| Vanguard Group Inc | $10,919.00 | 3.65% | 2.01M | +219,563 | +12.28% | 2025-09-30 |
| Portolan Capital Management, Llc | $7,530.00 | 2.52% | 1.38M | -237,586 | -14.65% | 2025-09-30 |
| Geode Capital Management, Llc | $5,049.00 | 1.69% | 928,197 | +24,227 | +2.68% | 2025-09-30 |
| Halter Ferguson Financial Inc. | $3,797.00 | 1.27% | 698,004 | -78,512 | -10.11% | 2025-09-30 |
| State Street Corp | $3,747.00 | 1.25% | 688,766 | +36,787 | +5.64% | 2025-09-30 |
| Sands Capital Alternatives, Llc | $2,208.00 | 0.74% | 405,837 | 0 | 0% | 2025-09-30 |
| Northern Trust Corp | $1,669.00 | 0.56% | 306,775 | +18,912 | +6.57% | 2025-09-30 |